Comparative Pharmacology
Head-to-head clinical analysis: QELBREE versus SUNOSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QELBREE versus SUNOSI.
QELBREE vs SUNOSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Qelbree (viloxazine) is a selective norepinephrine reuptake inhibitor (NRI) believed to exert its therapeutic effects by increasing norepinephrine levels in the prefrontal cortex, which enhances attention and reduces impulsivity/hyperactivity.
Selective dopamine and norepinephrine reuptake inhibitor; also acts as a TAAR1 agonist, increasing cAMP levels in monoamine neurons.
Initial: 0.5 mg orally once daily. Titrate by 0.5 mg increments every 2-3 days based on efficacy and tolerability to a maximum dose of 4 mg once daily. Target dose 2-4 mg once daily.
75 mg orally once daily upon awakening.
None Documented
None Documented
Terminal elimination half-life is approximately 14-17 hours in adults, supporting once-daily dosing. Steady-state is achieved within 7 days.
Terminal elimination half-life is approximately 9.5 hours in healthy adults; clinically relevant for once-daily dosing.
Primarily hepatic metabolism (CYP3A4-mediated) with <1% excreted unchanged in urine. Fecal elimination accounts for ~55% of the dose as metabolites; renal excretion accounts for ~40% as metabolites.
Primarily renal elimination (approximately 95% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%.
Category C
Category C
Norepinephrine Reuptake Inhibitor
Dopamine and Norepinephrine Reuptake Inhibitor